Articles tagged with Leukemia
A study by Dr Manel Esteller and colleagues identified an epigenetic signature associated with a good clinical response to hypomethylating drugs, enabling early detection of resistant patients. The research found single genes that facilitate the development of biomarkers and rescue strategies for non-responder patients.
The European LeukemiaNet has published two-part guidelines for adult acute lymphoblastic leukemia treatment, covering diagnostics, prognostic factors, response assessments, and comprehensive management. These recommendations are based on a decade of systematic work by European experts, improving the prognosis of adult patients with ALL.
Researchers at City of Hope have developed a new approach to target and destroy hard-to-kill leukemia stem cells. The therapy method uses Type II interferon to disrupt the cancer cells' ability to divide, and a T cell engager antibody to create a bridge between the immune system and the leukemia stem cells.
Researchers identified mechanisms that cause ponatinib to harm the heart and found a promising treatment that could reverse this process. The treatment protects heart cells without diminishing the tumor-fighting efficacy of the drug.
Researchers discovered a link between single cancer cell mutations and clinical response to epigenetic therapy in myelodysplastic syndrome. Patients showing treatment benefits had decreased mutation counts in stem cells and immature granulocytes, suggesting early tumor elimination is key to therapy success.
A pilot study proposes a promising global genomic assay for diagnosing molecular subtypes in pediatric B-ALL, leading to more accurate diagnosis and targeted treatment options. RNA sequencing analysis accurately identified subtypes in all known cases and determined genetic subtype in 79% of previously unknown cases.
Researchers discovered that combining fludarabine, melphalan, and low-dose total-body irradiation offers the best survival rate and lowest relapse rate in cord blood transplantation for myeloid malignancies. The study analyzed data from 1395 cases and found fewer deaths from infection with this combination.
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
Researchers at Tokyo Medical and Dental University characterize myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) using multiomics approaches, revealing distinct molecular features. This work provides crucial details for accurate diagnoses and therapeutic decisions.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
A microbial sensor, Nod1, plays a crucial role in the development of blood stem cells. The discovery could lead to the creation of patient-derived blood stem cells, eliminating the need for bone marrow transplants and improving lives of leukemia, lymphoma, and anemia patients. Researchers are continuing to study the complex interaction...
A phase III trial has found that personalised treatment for chronic lymphocytic leukaemia (CLL) can improve survival and remission rates. The trial showed that individualising therapy based on regular blood tests significantly improved progression-free and overall survival in patients with previously untreated CLL.
The study found that dasatinib and blinatumomab combination treatment resulted in excellent median overall survival and disease-free survival times for patients 65 and older with Philadelphia chromosome-positive acute lymphoblastic leukemia. The regimen confirmed benefits of this treatment are durable, with a median overall survival of...
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.
Researchers from the Mass General Cancer Center presented studies on psychiatric and substance use disorders as independent predictors of treatment response and outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia (AML) treated with Venetoclax Combinations. Additionally, a Phase 1 Study of CAR-T-ddBCMA for the...
A recent study by Goethe University Frankfurt has identified a mechanism that could be a suitable starting point for developing novel drugs against leukemia cells. The researchers discovered that the mutated NPM1 gene variant drives pro-autophagic activity, enabling cancer cells to recycle their structures and meet their needs.
Scientists at St. Jude Children's Research Hospital identified genes directly regulated by the oncogenic HOXA9 protein in high-risk pediatric leukemias. The study found two major targets, FLT3 and CDK6, which can be therapeutically targeted with drugs, showing promising outcomes in preclinical models. Additionally, researchers discover...
Researchers at Goethe University Frankfurt have identified a specific gene locus, MYNRL15, that is critical to the survival and replication of leukemia cells. Inhibiting this gene has been shown to deactivate genes necessary for AML cell survival, offering a new possibility for fighting leukemia.
Researchers created a comprehensive chromatin map to understand gene regulatory networks contributing to differences between pediatric acute lymphoblastic leukemia subtypes. The study identified key transcription factor footprints and chromatin accessibility patterns, which can predict leukemia subtype with 89% accuracy.
A study by researchers at the University of Illinois found a significant relationship between soy expansion and childhood leukemia deaths in Brazil. Pesticide use in the region has been linked to increased cancer mortality, with an estimated 123 children under 10 dying from ALL associated with pesticide exposure between 2008 and 2019.
Researchers developed a blood test to detect cancer earlier in individuals with Li-Fraumeni syndrome, an inherited condition with a high risk of developing cancer. The study provides a proof-of-principle framework for detecting specific cancers earlier, paving the way for further clinical trials and improved patient care.
A new cancer drug candidate has been found to restore the effectiveness of the immune system in fighting tumors, including melanoma, bladder cancer, leukemia, and colon cancer. The drug works by lowering a toxic compound called MTA, which impairs normal functioning of immune cells and blocks immunotherapies.
A new cell model has been created to simulate the evolution of a common form of childhood leukemia, B-cell acute lymphoblastic leukaemia. The model replicates the disease in children's cells, providing a crucial tool for researchers to develop new therapeutic strategies.
Researchers at St. Jude Children's Research Hospital refined the definition of hyperdiploidy in childhood B-cell acute lymphoblastic leukemia (B-ALL), using DNA index to predict patient outcomes. The study found that a simpler system captures a significant proportion of patients with excellent prognoses, and that individual chromosome ...
Dr. Hung Nguyen is studying how medium chain fatty acid foods like coconut oil and avocados affect GVHD severity and mortality in transplant patients. His goal is to develop a dietary approach that reduces inflammation and corticosteroid use, improving patient outcomes for blood cancers.
A subgroup analysis found that patients with an NPM1 mutation had a 48% reduced risk of death compared to those without the mutation. Patients receiving supplementation experienced lower rates of bacterial infections, bleeding, and inflammation during intensive chemotherapy.
A team of KAUST researchers has found a critical protein that regulates cell division and proliferation in breast cancer and leukemia. Their work clears the way for the development of targeted drugs by refuting recent challenges to their approach.
Researchers identified how low TET2 levels fuel rapid growth of acute myeloid leukemia in animal models. The study found that TET2 deficiency sets off biochemical changes enhancing the cancer's ability to spread. This discovery highlights potential therapeutic targets for treating aggressive bone marrow cancer.
A multicenter team has identified three risk biomarkers for chronic graft-versus-host-disease, which can be measured at 90 days after transplantation. These markers include MMP3, DKK3, and CXCL9, which are associated with fibrosis, inflammation, and immune cell attraction.
A study of 800 Dutch children found that modified treatment protocols increased the five-year survival rate for all children with acute lymphatic leukemia to 94%. The modifications resulted in a three times lower risk of disease recurrence, especially in children with an aggressive form of leukemia.
Researchers found that among individuals being treated for acute lymphoblastic leukemia, those overweight or obese had lower survival rates. The study suggests obesity may play an adverse role in response to ALL treatment regimens.
A prospective study of COVID-19 mRNA vaccines found progressively declining immune functions in individuals with chronic lymphocytic leukemia (CLL). The study, published in PLOS Medicine, showed that CLL patients experienced reduced antibody responses to the vaccines.
Researchers investigate MCL-1i-induced Mcl-1 protein accumulation and its implications in B-cell malignancies. The study reveals a complex mechanism contributing to MCL-1 protein stability upon treatment with MCL-1 inhibitors.
Researchers found that leukemia cells use messenger particles to navigate and release molecular cargo at distant sites, driving cancer metastasis. A potential therapeutic strategy involves targeting these particles with an antibody drug that blocks E-selectin activity.
Patients with high-risk CLL experienced durable responses to fixed-duration first-line treatment with ibrutinib in combination with venetoclax, with over 95% of patients achieving a response regardless of genetic features. The regimen also showed high survival rates at 36 months after treatment initiation.
Researchers uncover genetic changes that link blastic plasmacytoid dendritic cell neoplasm (BPDCN) to exposure to ultraviolet radiation, suggesting a potential role for sunlight in its development. The study, published in Nature, sheds light on how cancer cells evolve across multiple tissues.
The COMMANDS trial showed improved red blood cell counts and erythroid responses in transfusion-dependent patients with myelodysplastic syndromes, allowing the majority to no longer require regular blood transfusions. Luspatercept demonstrated superior effectiveness over epoetin alfa in this study.
A team from the University of Tsukuba has discovered that the enzyme ELOVL6 plays a significant role in the development of acute myeloid leukemia, a type of blood cancer. The study found that high levels of ELOVL6 are linked to shorter survival rates for leukemia patients.
A new Northwestern Medicine study found young adult cancer survivors (18-39 years old) are 2.6 times more likely to develop heart failure when treated with anthracyclines. The incidence is highest among leukemia and other specific cancer types.
Researchers have developed an automated calling algorithm for determining B and T cell clonality from NGS data with greater sensitivity than previous models. The new model increases the assay's sensitivity in detecting clonality, allowing for more accurate diagnosis and monitoring of lymphoproliferative disorders.
Researchers from Amsterdam UMC and Copenhagen University have found that a chemofree drug-combination therapy is more effective than traditional chemotherapy in treating CLL, resulting in reduced side effects and improved patient outcomes. The study, the largest ever conducted on CLL, involved 920 fit patients and showed that treatment...
Blinatumomab immunotherapy significantly improves the survival rate of babies with aggressive acute lymphoblastic leukemia (ALL), from 66% to 93%, while reducing side effects. The treatment is now standard for babies worldwide.
A study of 7807 children found no increased risk of brain tumours, leukemia, or lymphoma after a single CT scan. However, exposure to 4 or more scans before adulthood significantly increases the risk of intracranial tumours, leukemia, and non-Hodgkin lymphoma
Children with acute lymphoblastic leukemia (ALL) who live in extreme poverty are at a significantly higher risk of relapse and have difficulty adhering to treatment. The study highlights the need for clinicians and researchers to assess financial hardship and adherence to treatment to improve outcomes.
A study by Linköping University researchers found that blood stem cells from leukemia patients remain in the bone marrow, but become defective over time, leading to long-term effects on blood formation. This discovery may explain why many leukemia survivors experience blood cell function disorders later in life.
Researchers discuss cortactin's impact on cancer progression by modulating the Wnt5a/ROR1 signaling pathway. Cortactin expression is found in various cancers, including breast and chronic lymphocytic leukemia, suggesting its potential role in promoting metastasis.
Scientists from USC Stem Cell laboratory discovered a mechanism linking leukemic mutations to varying disease potentials, identifying RNA splicing regulator Rbm25 as a critical factor. The study found that over-contributing clones of blood stem cells produce excessive myeloid cells, leading to potential leukemia development.
Researchers at Lund University discovered a novel mechanism linking RNA splicing to the development of leukemia in myelodysplastic syndrome patients. The study highlights the critical role of core spliceosome component SF3B1 and its regulation by N6-methyladenosine (m6A) modification, which provides a
Researchers found that consuming vitamin A or its analogs can help prevent painful pancreas inflammation in children and young adults with acute lymphoblastic leukemia (ALL) during chemotherapy treatment. The study revealed that only 1.4% of patients developed pancreatitis when taking vitamin A, compared to 3.4% without it.
A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells. The therapy targets a DNA repair protein and shows promise in clinical trials.
A study of 2.2 million Danish children found certain maternal infections during pregnancy increased childhood leukemia risk among offspring. The findings suggest potential implications for etiology and preventive measures.
Researchers have successfully converted pluripotent stem cells into hematopoietic stem and progenitor cells using optimized transcription factors. The resulting PSC-derived cells generated all types of white blood cells in mice without giving rise to tumors or leukemias, suggesting a promising future for PSC-based transplant therapies.
A new protein degrader, AK-2292, shows promise against STAT5, a key player in leukemia and other cancers. By targeting the protein's degradation, researchers have overcome previous challenges in designing small molecule inhibitors.
Researchers at Harvard's Wyss Institute developed a method to fine-tune CAR-T cell stimulation using artificial antigen-presenting scaffolds. This approach enhances consistency and potency of resulting CAR-T cell products, allowing for better cancer treatment outcomes.
Researchers at VCU Massey Cancer Center have discovered a novel combination therapy that dramatically suppresses the growth of AML cells, including those resistant to venetoclax. The dual mTORC1/2 inhibitors synergistically enhance AML cell death when paired with venetoclax.
Pusan National University researchers have identified a novel gene, SURF4, that regulates cell death and differentiation in acute myeloid leukemia (AML). The study found that suppressing SURF4 expression increases cell differentiation, cell death, and accumulation of ROS, leading to arrested tumor growth in mice.
A new study standardizes the use of optical genome mapping (OGM) for patients with blood cancers, demonstrating its potential as a frontline test for diagnosing hematologic malignancies. OGM outperforms existing tests in detecting cancer-causing gene variants and identifying additional information that can improve patient outcomes.
Researchers from Hospital Universitario 12 de Octubre and Josep Carreras Institute create a cell therapy based on STAb cells for T-Cell Acute Lymphoblastic Leukemia (T-ALL), a rare disease with few treatment options. The new therapy offers an alternative to CAR-T therapies, which have limitations in treating this type of leukemia.
A comprehensive study of childhood leukemia's genetic diversity provides insights into personalized therapy. Researchers identified distinct groups based on drug sensitivity profiles, which significantly impact prognosis.
The E1910 trial found that adding blinatumomab to standard front-line consolidation chemotherapy improved overall survival and kept most patients in remission. The treatment, which targets malignant B cells, demonstrated its effectiveness in patients with a good prognosis after an initial round of chemotherapy.